EtNBS

EtNBS (5-ethylamino-9-diethylaminobenzophenothiazinium) is a cationic phenothiazinium photosensitizer developed for use in photodynamic therapy (PDT), particularly for the treatment of solid tumors and micrometastatic disease. Developed and extensively studied by researchers at Massachusetts General Hospital, EtNBS is designed to overcome the limitations of traditional photosensitizers in hypoxic tumor environments. Upon activation by specific wavelengths of light, it generates cytotoxic reactive oxygen species (ROS) and radical species through both Type I (radical-based) and Type II (singlet oxygen-based) photochemical pathways. In preclinical models of ovarian cancer, EtNBS has demonstrated the ability to penetrate and effectively kill cells within the cores of large tumor nodules that are often resistant to standard chemotherapeutics like cisplatin and carboplatin. It has also shown synergistic therapeutic effects when used in combination with platinum-based chemotherapy.

Other names

5-ethylamino-9-diethylaminobenzophenothiazinium chlorideEtNBS-Cl